Equine

Research Abstract

E14 - Prevention of Laminitis in Ponies Using Velagliflozin, a Novel Treatment for Insulin Dysregulation

Thursday, June 14
2:45 PM - 3:00 PM
Location: WSCC 620

The aim of this study was to determine if hyperinsulinaemia could be reduced and laminitis prevented in insulin-dysregulated ponies, by using the sodium-glucose co-transport 2 (SGLT-2) inhibitor velagliflozin. Forty-nine ponies with varying degrees of insulin dysregulation, based on an oral glucose test (1 g dextrose/kg BW), received either velagliflozin (0.3 mg/kg, p.o., s.i.d., n = 12), or a placebo (n = 37), throughout the study. A maintenance diet of lucerne hay was fed for 3 weeks, followed by a high-NSC challenge diet (12 g NSC/kg BW/day) for up to 18 days. On the second day of the diet challenge blood glucose and serum insulin were measured over 4 h after feeding. Results are expressed as geometric mean (95% CI). The maximum concentration of glucose was lower (P = 0.022) for the velagliflozin group at 9.4 mM (8.0 -11.0) versus 11.9 mM (10.5 -13.4) in controls; and likewise, the maximum concentration of insulin was lower for treated ponies at 149 mIU/mL (97 - 228) versus 269 mIU/mL (206 - 351) in controls (P = 0.017). Fourteen of the 37 controls (38%) developed Obel grade 1 or 2 laminitis, whereas none of the velagliflozin-treated ponies did (P = 0.011). As there were no clinical signs of adverse effects, velagliflozin could be a valuable tool for the prevention of insulin-associated laminitis and the treatment of insulin dysregulation in susceptible animals.

Alexandra Meier, BVSc (Hons)

PhD Candidate
Queensland University of Technology

Presentation(s):

Send Email for Alexandra Meier


Assets

E14 - Prevention of Laminitis in Ponies Using Velagliflozin, a Novel Treatment for Insulin Dysregulation

Handout

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prevention of Laminitis in Ponies Using Velagliflozin, a Novel Treatment for Insulin Dysregulation